ESTRO 37 Abstract book

Proffered Papers RB 5: Head and neck radiobiology.............................................................................. (Abs. 485-491) CL 9: Lung. ............................................................................................................ (Abs. 492-498) CL 10: Prostate....................................................................................................... (Abs. 499-505) PH 9: Analysis of treatment outcomes........................................................................ (Abs. 506-512) PH 10: Treatment planning 2..................................................................................... (Abs. 513-519) RTT 5: Motion management and adative stratgies. ....................................................... (Abs. 520-526) Poster Viewing Poster viewing 10: Images and analyses..................................................................... (Abs. 527-535) Randomised Trials Selected randomised trials........................................................................................ (Abs. 536-538) Award Lecture Klaas Breur Award Lecture.............................................................................................. (Abs. 539) Symposium Challenges in human resources in radiotherapy............................................................ (Abs. 540-543) Joint Symposium ESTRO-ESR: New imaging approaches for radiotherapy................................................. (Abs. 544-547) Symposium Biomarker driven hypoxic modification........................................................................ (Abs. 548-550) Debate This house believes that treatment intensification in stage III is a dream rather than a reality?............................................................................................... (Abs. 551-552) Symposium What’s new in the management of high risk prostate cancer patients in 2018?. ................ (Abs. 553-555) Outcome prediction models for RT indications - development, validation, acceptance, commissioning and application.................................................................................. (Abs. 556-558) Debate Is there still a place for patient specific QA?. ............................................................... (Abs. 559-560) Symposium Focus on site - BREAST. ........................................................................................... (Abs. 561-563) Poster Viewing Poster viewing 11: Emerging technologies: radiobiology and physics hand in hand............ (Abs. 564-572) Symposium Planning future global radiotherapy services................................................................ (Abs. 573-575) Normal tissue dose-response modelling across radiation modalities................................. (Abs. 576-579) Proffered Papers RB 6: Role and impact of Normal tissue RT response biology.......................................... (Abs. 580-586) CL 11: CNS. ........................................................................................................... (Abs. 587-593) CL 12: Late-breaking abstracts and practice changing trials........................................... (Abs. 594-600) PH 11: Emerging technologies................................................................................... (Abs. 601-607) PH 12: Audits and QA. ............................................................................................. (Abs. 608-614) RTT 6: Treatment planning and quality assurance......................................................... (Abs. 615-620) Poster Viewing Poster viewing 12: Prostate. ..................................................................................... (Abs. 621-629) Award Lecture Jens Overgaard Legacy Award......................................................................................... (Abs. 630) Academic award: Jack Fowler University of Wisconsin Award................................................ (Abs. 631) Company Award Lectures. ........................................................................................ (Abs. 632-633)

TUESDAY 24 APRIL 2018

Teaching Lecture Navigation in the publication ethics landscape: Publish or perish or...?................................... (Abs. 634) Risk Management: Quality and Safety New EU legislation and implementation........................ (Abs. 635) Normal tissue stem cells and cancer stem cells in radiation response. ................................... (Abs. 636)